-

Global Fertility Treatments Market Assessment 2020: Valued at $14.87 Billion in 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Fertility Treatments Market Global Report 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The global fertility treatments market was worth $14,870.3 million in 2019. Asia-Pacific was the largest region in 2019. Major players in the market are Apollo Hospitals Enterprise Ltd., Care Fertility Group, Genea Limited, The Johns Hopkins Health System Corp, Medicover Group, Monash IVF Group, Progyny Inc., Vitrolife, Carolinas Fertility Institute and OvaScience Inc.

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider fertility treatments market, and compares it with other markets.

The growth in the median age of first-time motherhood combined with change in lifestyle increased the difficulty of conceiving, increasing the demand for fertility treatment. The median age of first-time motherhood has increased all over the globe due to late marriages, contraceptive techniques, and increase in number of women who prioritize their careers over starting a family. According to statistics from the National Center for Health Statistics in 2018, the average age for having a first baby in the USA was 26.9 years, an increase from 22.7 years in 1980. In this scenario, a growing number of women are opting for IVF treatments, which is expected to drive this market.

The high cost and low success rate of In vitro fertilization (IVF) treatment is a major factor that limits the growth of the fertility treatments market. In vitro fertilization (IVF) treatment costs differs in many countries due to the lack of refund policies. Moreover, insurance companies usually do not cover infertility treatments. According to the American society of reproductive medicine, in the USA, the average cost of IVF cycle is $12,400 and the average cost of an IVF cycle using fresh embryos is $8,158 with median cost at $7,500. The rate of success of IVF treatments is only 28% to 35%, which decreases with the increase in woman's age. For example, for women, the success rate is 32.2% under 35 and 1.9% for women aged over 44. Thus, the high cost and low success rate of the IVF treatment restrict the growth of the fertility treatment market.

Development of new techniques to treat infertility using a human's body is a key trend in the fertility treatments market. INVOcell is an IVF alternative that uses the woman's body to support fertilization, thus eliminating the cost of a laboratory incubator. The INVOcell device is placed with the eggs and sperm in the vaginal cavity, allowing for the stability of the natural environment, pH, and gas to help in fertilization. INVOcell, which is made in Medford, Massachusetts by INVO Bioscience, costs around $6,800 including medication. Although IVF generated more quality embryos, the birth rates between IVF and INVOcell are similar. According to the journal of assisted reproduction and genetics in 2017, 12 out of 20 women gave birth to 15 babies in IVF including three sets of twins and 11 out of 20 women gave birth to 16 babies in INVOcell group including five sets of twins.

In April 2019, Silverfleet Capital, a European based company specialized in mid-market buyouts acquired Care Fertility for an undisclosed amount. Through this acquisition, Silverfleet Capital builds an extensive healthcare experience and aligns with its strategy of supporting companies with strong underlying dynamics of market growth. Care Fertility, a UK based company, offers a range of fertility treatments with a personalized approach to patient care.

Key Topics Covered

1. Executive Summary

2. Fertility Treatments Market Characteristics

3. Fertility Treatments Market Size and Growth

3.1. Global Fertility Treatments Historic Market, 2015-2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Fertility Treatments Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Fertility Treatments Market Segmentation

4.1. Global Fertility Treatments Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

  • Reagents
  • Equipment

4.2. Global Fertility Treatments Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

  • Fertility Clinics
  • Hospitals
  • Surgical Centers
  • Clinical Research Institutes

5. Fertility Treatments Market Regional and Country Analysis

5.1. Global Fertility Treatments Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5.2. Global Fertility Treatments Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned (A-Z)

  • Apollo Hospitals Enterprise Ltd.
  • Care Fertility Group
  • Carolinas Fertility Institute
  • Cook Medical
  • CooperSurgical, Inc.
  • CryoChoice, LLC
  • Ferring Pharmaceuticals
  • Fertility Focus
  • FUJIFILM Irvine Scientific
  • Genea Limited
  • Instituto Bernabeu
  • INVO Bioscience
  • Irvine Scientific sales Company, Inc.
  • LABOTECT GmbH
  • Medicover Group
  • Merck KGaA
  • Millendo Therapeutics, Inc.
  • Monash IVF Group
  • Olympus Corporation
  • OvaScience Inc.
  • Progyny Inc.
  • The Cooper Companies Inc.
  • The Johns Hopkins Health System Corp.
  • Virtus Health
  • Vitrolife
  • Xytex Cryo International

For more information about this report visit https://www.researchandmarkets.com/r/m2771s

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Blockchain and Non-Fungible Tokens new Technologies and the Relevant Law Training Course: Core Principles, Smart Contracts, NFTs, and Decentralized Finance Explained (Online Event: May 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blockchain and Non-Fungible Tokens: Understanding new Technologies and the Relevant Law Training Course (May 20, 2026)" training has been added to ResearchAndMarkets.com's offering. Blockchain is a new technology that could potentially have major impacts in a wide range of industries. It has the potential to dramatically change how business is conducted - but there is no one central authority controlling blockchain, everyone has access to the same information. Are...

Writing Clinical Research with Integrity Training Course: Principles of Medical and Scientific Writing, Including Ethical Standards, Data Integrity, and Plagiarism Prevention (Online: Apr 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Writing Clinical Research with Integrity Training Course (Apr 20, 2026)" training has been added to ResearchAndMarkets.com's offering. This course covers key principles of medical and scientific writing, including ethical standards, data integrity, and plagiarism prevention. Participants will learn how to tailor content for various audiences, structure documents (e.g., manuscripts, protocols), and adhere to writing standards such as clarity, consistency, and correc...

In-Vitro Diagnostic Regulation (EU) 2017/746 Introduction Training Course (Online Event: Apr 16th - Apr 17th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course (Apr 16th - Apr 17th, 2026)" training has been added to ResearchAndMarkets.com's offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation. The Regulation in...
Back to Newsroom